GlassScriptPhysician profile
Hew W Quon
NPI 1710074026
$28,394.85
in general payments reported to CMS, 2019-2025
38 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,285 · 2021: $930 · 2022: $1,680 · 2023: $2,991 · 2024: $2,163 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.66 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13,026.84 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,619.89 | 2019-2024 | Farxiga, Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,367.60 | 2019-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $1,105.05 | 2019-2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.51 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $780.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $775.79 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $622.36 | 2021-2024 | |
| Lilly USA, LLC | $590.03 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $569.00 | 2019-2024 | Repatha, Otezla |
| Gilead Sciences, INC. | $521.02 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $484.99 | 2019-2023 | Trintellix |
| Abbvie INC. | $459.74 | 2019-2024 | |
| Esperion Therapeutics, INC. | $417.04 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $392.68 | 2019-2024 | Verquvo, Steglatro, Belsomra |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $342.47 | 2019-2024 | Linzess |
| Allergan, INC. | $303.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $299.78 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $242.38 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $239.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.09 | 2019 | |
| Aimmune Therapeutics, INC. | $162.44 | 2024-2025 | Zenpep |
| Radius Health, INC. | $156.68 | 2019-2020 | |
| Pfizer INC. | $154.50 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $127.53 | 2019 | |
| Horizon Therapeutics Plc | $99.77 | 2019-2020 | |
| Vifor Pharma, INC. | $90.91 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $78.64 | 2019-2024 | Zoryve |
| Scilex Pharmaceuticals INC. | $68.14 | 2019-2020 | |
| Corium, LLC | $62.54 | 2023 | Adlarity |
| Lundbeck LLC | $56.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.55 | 2022 | |
| Sumitomo Pharma America, INC. | $40.07 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $29.91 | 2021 | |
| Astellas Pharma US INC | $24.22 | 2019 | |
| Genentech USA, INC. | $17.60 | 2019 | |
| Redhill Biopharma INC. | $17.20 | 2021 | |
| Cequr Corporation | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hew Quon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.